Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma.
Trilla-Fuertes L, Gámez-Pozo A, Nogué M, Busquier I, Arias F, López-Campos F, Fernández-Montes A, Ruiz A, Velázquez C, Martín-Bravo C, Pérez-Ruiz E, Asensio E, Hernández-Yagüe X, Rodrigues A, Ghanem I, López-Vacas R, Hafez A, Arias P, Dapía I, Solís M, Dittmann A, Ramos R, Llorens C, Maurel J, Campos-Barros Á, Fresno Vara JÁ, Feliu J. Trilla-Fuertes L, et al. Cancer. 2023 Aug 15;129(16):2581-2592. doi: 10.1002/cncr.34797. Epub 2023 Apr 25. Cancer. 2023. PMID: 37096763
Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.
Fernandez LM, São Julião GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, Hilling DE, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Renehan AG, van de Velde CJH, Habr-Gama A, Perez RO; International Watch & Wait Database Consortium. Fernandez LM, et al. Lancet Oncol. 2021 Jan;22(1):43-50. doi: 10.1016/S1470-2045(20)30557-X. Epub 2020 Dec 11. Lancet Oncol. 2021. PMID: 33316218
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A, Semac I, Vanhoutte F, Goetghebeur E, Reynders D, Ost P. Zilli T, et al. Eur Urol Focus. 2021 Mar;7(2):241-244. doi: 10.1016/j.euf.2020.12.010. Epub 2020 Dec 29. Eur Urol Focus. 2021. PMID: 33386290 Free article. Clinical Trial.
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
Romero-Laorden N, Lozano R, Jayaram A, López-Campos F, Saez MI, Montesa A, Gutierrez-Pecharoman A, Villatoro R, Herrera B, Correa R, Rosero A, Pacheco MI, Garcés T, Cendón Y, Nombela MP, Van de Poll F, Grau G, Rivera L, López PP, Cruz JJ, Lorente D, Attard G, Castro E, Olmos D. Romero-Laorden N, et al. Br J Cancer. 2018 Oct;119(9):1052-1059. doi: 10.1038/s41416-018-0123-9. Epub 2018 Aug 21. Br J Cancer. 2018. PMID: 30131546 Free PMC article. Clinical Trial.
Metformin and statins: a possible role in high-risk prostate cancer.
Cadeddu G, Hervás-Morón A, Martín-Martín M, Pelari-Mici L, Ytuza-Charahua de Kirsch K, Hernández-Corrales A, Vallejo-Ocaña C, Sastre-Gallego S, Carrasco-Esteban E, Sancho-García S, López-Campos F. Cadeddu G, et al. Rep Pract Oncol Radiother. 2020 Mar-Apr;25(2):163-167. doi: 10.1016/j.rpor.2019.12.027. Epub 2020 Jan 9. Rep Pract Oncol Radiother. 2020. PMID: 32021570 Free PMC article.
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R, Salles DC, Sandhu S, Aragón IM, Thorne H, López-Campos F, Rubio-Briones J, Gutierrez-Pecharroman AM, Maldonado L, di Domenico T, Sanz A, Prieto JD, García I, Pacheco MI, Garcés T, Llacer C, Romero-Laorden N, Zambrana F, López-Casas PP, Lorente D, Mateo J, Pritchard CC, Antonarakis ES, Olmos D, Lotan TL, Castro E. Lozano R, et al. Eur J Cancer. 2021 Apr;147:74-83. doi: 10.1016/j.ejca.2021.01.027. Epub 2021 Feb 21. Eur J Cancer. 2021. PMID: 33626496
Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma.
Duque-Santana V, López-Campos F, Martin M, Pelari L, Hernandez A, Valero M, Galindo J, Priego P, Cuadrado M, Longo F, Caminoa-Lizarralde M, Sancho S. Duque-Santana V, et al. Rep Pract Oncol Radiother. 2022 Jul 29;27(3):500-508. doi: 10.5603/RPOR.a2022.0054. eCollection 2022. Rep Pract Oncol Radiother. 2022. PMID: 36186695 Free PMC article.
Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?
Arcos MBL, López-Campos F, Valcarcel ML, Rubio MG, de Manzanos IVF, Duque-Santana V, Aparicio MG, Martin JZ, Kishan AU, Achard V, Siva S, Couñago F. Arcos MBL, et al. Clin Genitourin Cancer. 2023 Jun;21(3):e93-e103. doi: 10.1016/j.clgc.2022.10.015. Epub 2022 Nov 11. Clin Genitourin Cancer. 2023. PMID: 36456467 Review.
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R, Castro E, Lopez-Campos F, Thorne H, Ramirez-Backhaus M, Aragon IM, Cendón-Florez Y, Gutierrez-Pecharroman A, Salles DC, Romero-Laorden N, Lorente D, González-Peramato P, Calatrava A, Alonso C, Anido U, Arévalo-Lobera S, Balmaña J, Chirivella I, Juan-Fita MJ, Llort G, Y Cajal TR, Almagro E, Alameda D, López-Casas PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio-Briones J, Sandhu S, Olmos D. Lozano R, et al. Eur J Cancer. 2023 May;185:105-118. doi: 10.1016/j.ejca.2023.02.022. Epub 2023 Mar 5. Eur J Cancer. 2023. PMID: 36972661
57 results